Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 20 (12), 1750-1759, 2019-12
Elsevier BV